Inspire Medical Systems (NYSE:INSP) Reaches New 12-Month Low on Analyst Downgrade

Key Points

• Shares hit a new 52-week low after JPMorgan cut its price target to $54 and multiple brokers lowered targets, with the stock trading as low as $44.41 and last at $48.24.
• Q1 beat estimates—$0.10 EPS vs. -$0.28 est. and $204.6M revenue—but management sharply cut FY‑2026 guidance to $0.75–$1.25 EPS and $825M–$875M revenue, citing reimbursement/coding uncertainty and WISeR disruptions.
• Analyst views are mixed (four Buys, fifteen Holds, one Sell; consensus "Hold"), while institutional ownership is high (~94.9%) and the company has a market cap of about $1.39B.

Inspire Medical Systems, Inc. (NYSE:INSP - Get Free Report)'s share price hit a new 52-week low on Wednesday after JPMorgan Chase & Co. lowered their price target on the stock from $67.00 to $54.00. JPMorgan Chase & Co. currently has a neutral rating on the stock. Inspire Medical Systems traded as low as $44.41 and last traded at $48.2390, with a volume of 4487693 shares. The stock had previously closed at $54.84.

A number of other equities analysts have also commented on INSP. Evercore set a $55.00 price objective on shares of Inspire Medical Systems in a report on Tuesday. Truist Financial cut their price objective on shares of Inspire Medical Systems from $64.00 to $50.00 and set a "hold" rating on the stock in a report on Tuesday. Robert W. Baird cut their price objective on shares of Inspire Medical Systems from $63.00 to $50.00 and set a "neutral" rating on the stock in a report on Tuesday. UBS Group set a $67.00 price objective on shares of Inspire Medical Systems in a report on Friday, February 13th. Finally, Stifel Nicolaus cut their price objective on shares of Inspire Medical Systems from $70.00 to $65.00 and set a "buy" rating on the stock in a report on Tuesday. Four analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $85.00.

Inspire Medical Systems News Summary

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q1 beat consensus — reported $0.10 EPS (vs. est. -$0.28) and $204.6M revenue (vs. est. ~$200M), showing the underlying business still generates profitability. Q1 Press Release
• Positive Sentiment: Some brokers kept constructive stances (Stifel maintained a "buy" and Mizuho an "outperform") even after lowering targets, which provides potential upside if guidance risks ease. Analyst Reactions (Benzinga)
• Neutral Sentiment: Bank of America reaffirmed a neutral rating with a $53 target — a modestly cautious view that mirrors the market’s wait‑and‑see stance. BofA Reaffirmation
• Negative Sentiment: Management cut FY‑2026 guidance to $0.75–$1.25 EPS and $825M–$875M revenue vs. consensus ~ $1.99 EPS and ~$961M revenue — the sizable guidance cut is the primary negative catalyst. FY‑2026 Guidance Cut
• Negative Sentiment: Company cited reimbursement/coding uncertainty and disruptions from the WISeR program that have reduced procedure volumes — operational headwinds that could pressure near‑term revenue recovery. Reimbursement & WISeR Issues
• Negative Sentiment: Multiple brokers cut price targets (JPMorgan $67→$54; Wells Fargo $70→$56; Truist $64→$50; Baird $63→$50), shifting consensus lower and adding selling pressure despite some remaining buy/outperform ratings. Analyst PT Moves (JPMorgan/TickerReport)

Institutional Investors Weigh In On Inspire Medical Systems

A number of institutional investors have recently modified their holdings of the stock. Principal Financial Group Inc. raised its stake in shares of Inspire Medical Systems by 1.0% in the 1st quarter. Principal Financial Group Inc. now owns 126,788 shares of the company's stock valued at $6,540,000 after purchasing an additional 1,269 shares in the last quarter. Fifth Third Bancorp raised its stake in shares of Inspire Medical Systems by 1,794.4% in the 1st quarter. Fifth Third Bancorp now owns 6,441 shares of the company's stock valued at $332,000 after purchasing an additional 6,101 shares in the last quarter. New York State Teachers Retirement System raised its stake in shares of Inspire Medical Systems by 9.3% in the 1st quarter. New York State Teachers Retirement System now owns 23,599 shares of the company's stock valued at $1,217,000 after purchasing an additional 2,004 shares in the last quarter. Y Intercept Hong Kong Ltd raised its stake in shares of Inspire Medical Systems by 124.1% in the 1st quarter. Y Intercept Hong Kong Ltd now owns 158,274 shares of the company's stock valued at $8,164,000 after purchasing an additional 87,639 shares in the last quarter. Finally, Leonteq Securities AG raised its stake in shares of Inspire Medical Systems by 187.3% in the 1st quarter. Leonteq Securities AG now owns 22,812 shares of the company's stock valued at $1,177,000 after purchasing an additional 14,873 shares in the last quarter. Institutional investors and hedge funds own 94.91% of the company's stock.

Inspire Medical Systems Stock Performance

The firm has a market cap of $1.39 billion, a price-to-earnings ratio of 10.74, a price-to-earnings-growth ratio of 2.83 and a beta of 0.83. The business's 50 day moving average price is $56.51 and its 200-day moving average price is $79.43.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its quarterly earnings data on Monday, May 4th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.38. The firm had revenue of $204.58 million for the quarter, compared to analyst estimates of $200.04 million. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.66%. Inspire Medical Systems's quarterly revenue was up 1.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.10 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. On average, analysts forecast that Inspire Medical Systems, Inc. will post 1.82 earnings per share for the current fiscal year.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.